1. Show article details.

    Repligen to Report Third Quarter 2021 Financial Results

    GlobeNewswire – 7:30 AM ET 10/14/2021

    Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT Repligen Corporation (RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021. The conference call will be accessible by dialing toll-free 274-3999 for domestic callers and 317-5607 for international callers.

  2. Show article details.

    Analysis-Growth funds among Q3 winners for U.S. investors as COVID worries grew

    Reuters – 1:26 AM ET 09/30/2021

    U.S. mid-cap growth funds, emerging market stocks and inflation-protected bonds were among the winners for U.S. investors in a turbulent third quarter that saw the benchmark S&P 500 hit a record high only to tumble at the end of September as rising Treasury yields and debt negotiations in Washington weighed on investor sentiment.

  3. Show article details.

    BRIEF-Repligen Reports Agreement To Acquire Avitide

    Reuters – 7:43 AM ET 09/16/2021

    Repligen Corp (RGEN): * REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE AVITIDE INC. * Repligen Corp (RGEN) - TO ACQUIRE PRIVATELY-HELD AVITIDE INC FOR ABOUT $150 MILLION. * Repligen Corp (RGEN) - AVITIDE IS EXPECTED TO BE ACCRETIVE TO CO'S ADJUSTED EARNINGS PER SHARE IN 2023. * Repligen Corp (RGEN) - DEAL COMPRISED OF $75 MILLION IN CASH PLUS $75 MILLION IN REPLIGEN STOCK Source text for Eikon: Further company coverage:

  4. Show article details.

    Repligen Announces Agreement to Acquire Avitide Inc.

    GlobeNewswire – 7:40 AM ET 09/16/2021

    WALTHAM, Mass., Sept. 16, 2021 -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen (RGEN) common stock in addition to performance-based earnout payments over the...

  5. Show article details.

    BRIEF-Repligen And Navigo GmbH Announce Launch Of Industry-First Protein A Ligand For Purification Of Ph Sensitive Antibodies

    Reuters – 8:06 AM ET 09/09/2021

    Repligen Corp (RGEN): * REPLIGEN AND NAVIGO GMBH ANNOUNCE LAUNCH OF INDUSTRY-FIRST PROTEIN A LIGAND FOR PURIFICATION OF PH SENSITIVE ANTIBODIES Source text for Eikon: Further company coverage:

  6. Show article details.

    Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

    GlobeNewswire – 7:30 AM ET 09/09/2021

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH, today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins.

  7. Show article details.

    BRIEF-Repligen Corp Extended Long-Term Supply Agreement With Cytiva Sweden AB Through 2025

    Reuters – 7:53 AM ET 09/03/2021

    Repligen Corp (RGEN): * Repligen Corp (RGEN) - ANNOUNCED THAT IT HAS EXTENDED THROUGH 2025 A LONG-TERM SUPPLY AGREEMENT WITH CYTIVA SWEDEN AB. * Repligen Corp (RGEN)- EXTENDS AGREEMENT FOR CONTRACT MANUFACTURE OF CYTIVA LIGANDS AT THE COMPANY'S FACILITIES IN WALTHAM, MA AND LUND, SWEDEN Source text for Eikon: [https://bit.ly/3yIEx2M] Further company coverage:

  8. Show article details.

    BRIEF-Repligen Reports Q2 EPS Of $0.64

    Reuters – 9:47 AM ET 07/27/2021

    Repligen Corp (RGEN): * REPLIGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 FINANCIAL GUIDANCE. * Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.79. * Q2 GAAP EARNINGS PER SHARE $0.64. * Q2 EARNINGS PER SHARE ESTIMATE $0.52 -- REFINITIV IBES DATA. * SEES FY REVENUE UP 71 TO 76 PERCENT. * SEES FY REVENUE $625 MILLION TO $645 MILLION.

  9. Show article details.

    Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

    GlobeNewswire – 7:30 AM ET 07/27/2021

    WALTHAM, Mass., July 27, 2021 -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2021. Tony J. Hunt, President and Chief Executive Officer said, “We delivered an outstanding second quarter and first half of the year for the Company, with strength across the board in all our franchises.

  10. Show article details.

    Repligen to Report Second Quarter 2021 Financial Results

    GlobeNewswire – 7:30 AM ET 07/13/2021

    Repligen Corporation (RGEN) today announced that the Company will report its second quarter 2021 financial results on Tuesday, July 27, 2021. Image: Primary Logo.

  11. Show article details.

    Repligen Corporation Announces Agreement to Acquire Polymem S.A.

    GlobeNewswire – 6:30 AM ET 06/22/2021

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A., a leading industrial expert in the development and manufacture of hollow fiber membranes and modules.

  12. Show article details.

    Repligen Corporation to Present at Upcoming Investor Conferences

    GlobeNewswire – 7:30 AM ET 05/25/2021

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. A live webcast of the discussions will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

  13. Show article details.

    Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

    GlobeNewswire – 7:30 AM ET 05/04/2021

     Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Tony J. Hunt, President and Chief Executive Officer said, “I am extremely proud of the way our team executed here in the first quarter. First Quarter 2021 Highlights Financial Details for the First Quarter 2021 REVENUE.

Page:

Today's and Upcoming Events

  • Oct
    28

    RGEN to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Jul
    27

    RGEN announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.